HIGHER VALUES IN LIVER ELASTOGRAPHY AND MELD SCORE ARE MORTALITY PREDICTORS ON LIVER TRANSPLANT WAITING LIST

Valores mais altos na elastografia do fígado e pontuação MELD são preditores de mortalidade na lista de espera do transplante de fígado

Lucas Souto NACIF1, Denise C PARANAGUA-VEZOZZO1, Alina MATSUDA1, Venancio Avancini Ferreira ALVES2, Flair J CARRILHO1, Alberto Queiroz FARIAS1, Luiz Carneiro D’ALBUQUERQUE1, Wellington ANDRAUS1

How to cite this article: Nacif LS, Paranaigua-Vezozo DC, Matsuda A, Alves VAF, Carrilho FJ, Farias AQ, D’Albuquerque LC, Andraus W. Higher values in liver elastography and meld score are mortality predictors on liver transplant waiting list. ABCD Arq Bras Cir Dig. 2018;31(1):e1360. DOI: /10.1590/0102-672020180001e1360

From the 1Disciplina de Transplante de Órgãos do Aparelho Digestivo, Laboratório de Investigações Médicas (LIM 37), Departamento de Gastroenterologia, Faculdade de Medicina, Universidade de São Paulo and Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo (Liver and Gastrointestinal Transplant Division, Department of Gastroenterology, School of Medicine, University of São Paulo and Department of Pathology, School of Medicine, University of São Paulo), São Paulo, SP, Brazil.

HEADINGS - Liver transplantation. End-stage liver disease. Logistic models. Survival analysis.

Correspondence:
Lucas Souto Nacif
E-mail: lucasnacif@usp.br

Financial source: none
Conflict of interest: none

Received for publication: 23/11/2017
Accepted for publication: 01/02/2018

DESCRITORES - Transplante de fígado. Estágio final da doença hepática. Modelo para estágio final da doença de fígado. Regressão logística. Sobrevida de pacientes.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most important malignant liver tumor with increasing incidence and prevalence in the Western countries, mainly related to chronic hepatitis C infection and subsequent development of liver cirrhosis. As a result of surveillance programs aimed at identifying HCC at early stages, many patients have been eligible for curative interventions such as liver transplantation (LT). The current guidelines of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases recommend LT as the preferred alternative in most patients within the Milan criteria.

Over the last decade, it was noted the development and improvement of methods for predicting the degree of fibrosis and cirrhosis using non-invasive liver elastography.
methods, and there are important scores and biomarkers of fibrosis that help the identification of the clinical cirrhosis stages. These methods are based on image as unidimensional ultrasound with transient elastography (FibroScan), as well as ultrasound bidimensional in elastometry by ARFI (Acoustic Radiation Force Impulse). But, on another way, the real and potential role of these methods on advanced and complicated liver chronic disease is not yet clear. Recent studies have reported ultrasound-based techniques such a shear wave-based elastography like dispersion ultrasonic vibrometry or elastography point quantification capable useful predictor of malignancy and to screen for hepatocellular carcinoma. However, the data on the stiffness of HCCs and their background livers are controversy.

In this scenario, the progression of fibrosis and the onset of cirrhosis are important prognostic factors for patients on the liver transplantation waiting list. The majority of complications and mortalities are related to the severity of cirrhosis, and portal hypertension and its associated complications. The validation of the ability of elasticity quantification to reveal in real life, liver stiffness as an important factor for its widespread applications.

The objective of this study was to show the ability to perform an early diagnosis and choose the best treatment to improve the long-term survival rates and identify morbimortality risk on liver transplantation waiting list. Furthermore, this study aimed to assess liver stiffness, ultrasound and clinical findings in cirrhotic patients with and without HCC on screening for liver transplant.

**METHODS**

This study was approved by the Institutional Review Board with number 279.864 on May 22 of 2013 fulfilling all requirements for prospective studies in humans, following the guidelines of the 1975 Declaration of Helsinki.

From October 2012 to December 2013, a total of 103 consecutive adult patients (68% men, mean age 52±11.5 years) due to end-stage liver diseases were submitted to clinical, radiological, elastography and laboratorial assessment.

The following variables were analyzed: 1) demographics parameters: age, gender, etiology of the liver disease (viral/ non-viral); 2) clinical features: significant portal hypertension (defined as a hepatic vein pressure gradient (HPVG) ≥10 mmHg or the presence of gastro-esophageal varices, splenomegaly (>12 cm) with platelets count <100,000 cells/mm³, and need for diuretics to control ascites). When these criteria were present but hepatic portal vein measurement was not available portal hypertension clinically-based was diagnosed), Child-Turcotte-Pugh (A/B/C); 3) radiological findings and Doppler ultrasound 4) serum laboratory analysis: bilirubin (mean and median values), alpha fetoprotein (were compared according the cut off value obtained by the area under the receiver operating characteristics (AUROC) curve and values ≥20 or <20 values); 5) elastography findings (mean, median values and the cut off value) comparison with Model for End-stage liver disease (MELD) score; and 6) morbidity and mortality (comparison with MELD score).

**Elastography (FibroScan and ARFI)**

An important goal of this study was to perform and to compare data from transient elastography (TE) acquired by FibroScan™ (Echosens, France) and Acoustic Radiation Force Impulse (ARFI) as Virtual Touch™ (Siemens Acuson S2000, Germany) in the groups with and without HCC according the recent EASL/AASLD diagnostic guideline for HCC. Was used Acoustic Radiation Force Impulse (ARFI) to compare the liver stiffness between tumoral and non-tumoral liver parenchyma.

**RESULTS**

**Elastography technique**

The TE was performed with the patient placed in a bed after 2 h of fasting in the supine position with the right arm upright and under the head. The transducer gently touched the patient’s skin, in the right intercostal space between the 9th and 10 ribs, preferably choosing the reference position located at the intersection between the xyphoid and the median axillary lines at the point where hepatic biopsy is usually recommended.

The screen with three ultrasound signal evaluations had to show a regular liver wave in M mode, a linear A signal away from the large vessels and an elastogram equivalent to a finger’s width. The images were obtained when the operator observed the best conditions, as mentioned earlier. After 10 shots or 60% successful shots and an interquartile range (IQR) less than 30%, was considered valid measurement. The results were registered in numbers and expressed in kilopascals (kPa). The possible values in TE range from 2-75 kPa.

Following TE, ARFI was performed at the same intercostal point, and the exam was performed by the same experienced operator (with over 1000 exams performed). Were collected 10 measurements in the same place that the region of interest (ROI) was found, and the interquartile range was observed to obtain 30% less than the median final value, according to the European Association for the Study of the Liver Diseases (EASL) and World Federation for Ultrasound in Medicine and Biology (WFUMB) guidelines. Results of ARFI are reported in meters per second at a range of between 0.5 to 4.0 m/s.

There were relatively few unreliable ARFI results, although considered, because the interquartile range variation is usually larger in complicated cirrhosis, according to a recently published paper. This finding could be related to the presence of HCC alongside heterogeneous cirrhosis.

**Inclusion and exclusion criteria**

Adult patients with cirrhosis undergoing screening for HCC or on the LT waiting list were considered consecutively for inclusion. Informed consent was obtained from all participants. Patients with problematic anatomy, such as those with narrow intercostal spaces and small right hepatic lobes (n=1), high body mass indices (n=2), ascites (n=4), nodule diagnosed as something other than HCC (n=5) or a success rate <60% in 10 measurements on Fibroscan examination (n=16), were all excluded. Were excluded 28 patients out of 131 and included 103 patients in this study. Were excluded all patients with possible acute alcoholic hepatitis.

**Statistical analysis**

Median values (25% quantile – 75% quantile) were presented for quantitative variables and percentages for qualitative variables. Mann-Whitney test was performed to evaluate the difference between median from two groups and Fisher test was considered to verify the association. Furthermore, ANOVA or Kruskal-Wallis followed by non-parametric Turkey test were applied to find differences among groups and was performed simple and multiple logistic regression with statistical program in R, version 2.15.1. Finally, ROC Curve allowed to finding cutoffs for exams. A value of p<0.05 was considered significant in the final analysis. Follow-up was performed from the date of the first exam session until death, the last visit or the date of LT. Follow-up was continued until December 31, 2013. Clinical examination and laboratory data collection were routinely performed.

**Clinical and demographic parameters**

Baseline characteristics of the enrolled patients are...
presented in Table 1. The median age was 55 years old (20–77), and 70/103 (68%) patients were male. The etiology was hepatitis C, ethanol, hepatitis B, NASH and miscellaneous etiologies in 35%, 29%, 8%, 7% and 21% of patients, respectively. The presence HCC in patients with hepatitis C had significant statistical finding (p<0.0001). Thirty-eight (38%) patients were CPT A, 47 (47%) were CPT B and 15 (15%) were CPT C. The mean MELD score was 14.7 ± 6 and median was 14 (6–32). The BMI score mean was 28 ± (6). The ethnecities were white, brown, black and yellow; with respectively 69%, 24%, 6% and 1%. The encephalopathy was presented in 27%. The significant portal hypertension (PH-CB) was presented in 84% of the patients and these finding had significant difference in groups with and without HCC (p=0.038).

### Table 1 - Baseline characteristics of the enrolled patients

| Parameters          | Total (103) | HCC (44) | Non-HCC (58) | p     |
|---------------------|-------------|----------|--------------|-------|
| Age (y)             | 53 ± 11.5   | 54 ± 12.2 | 52 ± 11.0    | 0.448 |
| Gender (M/F) %      | 68/32       | 69/31    | 68/32        | >0.05 |
| Etiology %          |             |          |              |       |
| HCV                 | 35          | 51       | 21           |       |
| OH                  | 29          | 4        | 50           |       |
| HBV                 | 8           | 18       | 0            |       |
| NASH                | 7           | 4        | 9            |       |
| Cryptogenic         | 6           | 4        | 7            |       |
| CBS                 | 5           | 2        | 7            |       |
| Auto immune         | 3           | 7        | 0            |       |
| Others              | 7           | 5        | 7            |       |
| MELD score          |             |          |              | 0.693 |
| Mean                | 14.7 ± 6.4  | 14.7 ± 7.0 | 14.7 ± 6.0  | <0.001|
| Median              | 14 (6–32)   | 12 (6–30) | 14 (6–32)    |       |
| CT/ABC/C %          | 38/47/15    | 43/45/12 | 35/50/15     | 0.801 |
| AFP (≥20 ng/mL) %   | 25.7        | 38.9     | 10.3         | 0.011 |
| AFP (≥9.1 ng/mL) %  | 33.3        | 50       | 13.7         | 0.003 |
| PH-CB %             | 83.9        | 73.6     | 91.7         | 0.038 |

The FibroScan values of the HCV and ethanol etiologies were statistically different among groups without HCC (p=0.022), whereas the liver stiffness of the ethanol etiology was higher, approximately double the value of elastography in HCV etiology (Table 3).

### Table 2 - Elastography findings of the enrolled patients

| Parameters          | Total (103) | HCC (44) | Non-HCC (58) | p     |
|---------------------|-------------|----------|--------------|-------|
| FibroScan (kPa)     |             |          |              |       |
| Mean                | 32.73 ± 22.5 | 30.42 ± 21.0 | 35.6 ± 23.9 | 0.891 |
| Median              | 26.3 ± 3.85 | 24.6 (4.6-7.5) | 33.3 ± 23.9 |       |
| ARFI (m/s)          |             |          |              |       |
| Mean                | 2.02 ± 0.59 | 1.97 ± 0.64 | 2.06 ± 0.54 | 0.565 |
| Median              | 2.17 (0.65–3.4) | 1.98 (0.65–3.2) | 2.21 (0.88–3.4) |       |

The most prevalent hepatopathy with higher mortality was due alcohol in 55% (n=5), followed by HCV (n=2), cryptogenie in one case, and also chronic liver disease in only one case. The average value found in this population by FibroScan was 50.87 kPa and by the ARFI was 2.02 m/s. The patients who earlier died in this follow up had high values in elastography and in MELD score (p<0.05, Table 4)

### Table 3 – Comparison between Fibroscan® and ARFI® liver stiffness of ethanol (OH) and HCV etiology among groups with and without HCC and MELD score analysis

| Parameters/Groups | HCC_HCV (n=21) | Non-HCC_HCV (n=9) | p     |
|-------------------|---------------|------------------|-------|
| FibroScan® (kPa)  | 30.89 ± 4.09  | 22.1 ± 4.04      | 0.353 |
| ARFI® (m/s)       | 2.14 ± 0.12   | 2.06 ± 0.09      | 0.647 |

The accuracy diagnosis showed an improvement when the TE value was combined with ARFI values and serum AFP levels. The ROC curves showed the diagnostic accuracy with best cut-off value for FibroScan (9 kPa), ARFI (2.56 m/s) and AFP (9.1 ng/ml), with a sensitivity of 92% on Fibroscan and a specificity of 92% on ARFI. These accuracy diagnosis parameters

### Table 4 – Transient elastography (Fibroscan), ARFI, and MELD score assessing mortality

| Parameters | Death | Live (n=63) | p     |
|------------|-------|------------|-------|
| FibroScan® (kPa) n=4 | 50.87 ± 20.9 | 31.65 ± 22.2 | 0.098 |
| ARFI® (m/s) n=9 | 2.02 ± 0.37 | 2.02 ± 0.57 | 0.994 |
| MELD score n=9 | 21.00 ± 6.09 | 14.01 ± 6.25 | 0.035 |

The FibroScan values of the HCV and ethanol etiologies were statistically different among groups without HCC (p=0.022), whereas the liver stiffness of the ethanol etiology was higher, approximately double the value of elastography in HCV etiology (Table 3).
demonstrate an increased risk of HCC when a TE cut-off was higher than 9 kPa in general and 26.3 kPa in HCV patients. A cut-off for ARFI of 2.56 m/s included a higher percentage of HCC patients, around 73%.

**Logistic Regression**

Regression analysis for HCC detection was performed in the univariate analysis and the following variables were significant different between HCC and non-HCC group: gender, ethnicity, symptoms, ascitis, encefalopathy, portal hypertension clinically-based, diagnosis and elastography (Table 5). On the multiple regression analysis, only three variables statistically correlated with the presence of HCC: serum alpha fetoprotein level > 20 ng/ml, diagnosis, and hepatitis C virus etiology with the highest odds ratio (OR, Table 5).

| TABLE 5 - Regression analysis for HCC detection: simple and multiple logistic regression analysis |
| --- |
| Variables | Odds Ratio | 95% CI | p |
| HCV etiology | 26.84 | 5.44–132.35 | <0.0001 |
| Others etiology | 16.48 | 3.41–79.51 | <0.0001 |
| Ascitis | 0.42 | 0.18–0.93 | 0.033 |
| AFP (≥20 ng/mL) | 5.51 | 1.4–21.69 | 0.015 |
| Encephalopathy | 0.76 | 0.31–1.85 | 0.546 |
| PH-CB | 0.25 | 0.07–0.89 | 0.032 |
| Fibroscan (>9 kPa) | 1.75 | 0.45–6.8 | 0.419 |
| ARFI (>2.56 m/s) | 2.78 | 0.66–11.69 | 0.162 |

**Endpoints**

The study concluded after 12 months, or if the patient dropped out (34 patients dropped out, 14 with unfavorable clinical conditions, 10 with low MELD score and two were with tumor drop out Milan criteria and one loss of clinical follow up); died (n=9) or underwent definitive clinical intervention (LT in seven with 86% of one year survival rate) prior to this. The patients were then grouped according to mortality: 63/103 patients (65%) survived in follow up on the 12 months, while 9/103 (8.7%) did not. The most prevalent hepatopathy for mortality was alcoholic cirrhosis at 55% (n=5), followed by HCV (n=2), cryptogenesis in one case, and chronic liver disease, also in only one case. A further 31 dropped out or underwent LT. The survival group had a mean Fibroscan score of 31.65±22.2 kPa, while those who died showed a mean score of 50.87±20.9 kPa. The difference between the means is very close to statistical significance (p=0.098, Table 4).

**DISCUSSION**

The present study confirms that increased liver stiffness, serum alpha fetoprotein level, hepatitis C virus etiology and portal hypertension clinically-based (PH-CB) are predictors of the presence of HCC in liver cirrhosis patients. This study is a pioneer in the evaluation of patients by liver elastography in screening program for liver transplantation with severe liver disease patients, with higher clinical portal hypertension and almost all cases with class Child-Turcotte–Pugh B/C liver function. So, the importance of this study is to highlight that increased liver stiffness is associated with higher mortality but not well in real life to predict HCC.

Liver stiffness measurement using transient elastography is recognized as accurately able to assess the stage of liver fibrosis in patients with chronic hepatitis C virus infection even as was observed in this study. But the main importance of this cohort is that almost 84% of the patients had significant portal hypertension and advanced chronic liver disease. Moreover, the transient liver elastography shows high values in both HCC and cirrhosis livers and does not help to differentiate between them.

Patients with higher values of elastography measurements that mainly reflect the liver fibrosis progression of the cirrhotic patients are associated with HCC. Therefore, it is also supposed that elastography measurements might be a valuable noninvasive tool for assessing the presence and risk of developing HCC. To our knowledge, first studies reported a cut-off value of 53.7 kPa as suggestive for the presence of HCC in HCV cirrhotic patients. However, in this cohort, was found a lower cut-off value by Fibroscan of 26.3 kPa in HCV patients and 9kPa in the general group with increased risk of HCC.

Masuzaki et al. observed that patients with chronic HCV liver disease stratified by elastography were presented variable risk of HCC per year depending on the value obtained by the TE method. In this study, was also observed that higher liver stiffness get by TE and ARFI methods associated with increased values of serum AFP and etiology of hepatitis C virus (HCV). Therefore, risk factors for the development of hepatocellular carcinoma in these patients were the presence of hepatitis C virus, the serum AFP with cutoff point higher than 9.1 ng/dl and elastography values greater than 9kPa in FibroScan and higher than 2.56 m/s in ARFI.

Trinchet et al. conducted a prospective, randomized controlled trial with ultrasound every 3-6 months and they found a higher number of false positives in the lower range arm, and also recommended reduced the intervals in suspected smaller lesion every three months. In our clinical service, we followed a total of 884 cirrhotic patients by ultrasound and AFP serum were analyzed at least one time per year during 5–10 years and they observed the presence of HCC in 72 cases (8.1%) and an annual incidence rate of HCC of 2.8%. Thus, probably patients with alcoholic cirrhosis should remain in a surveillance every six months, but in patients with hepatitis C when they get by TE value higher than 26.3 kPa, it is indicated a tracking every three months due to the higher risk of developing HCC.

The advanced fibrosis and cirrhosis are different among the various etiologies and this statement has been confirmed by the literature over the years, clearly demonstrated by pioneering study in late 1950’s with assessments based on analysis of 10,000 consecutive autopsies. In our study, we compared the elastography values of patients without HCC in ethanol and HCV etiology, and we observed the double values obtained by FibroScan (p=0.022) with similar CHILD and MELD. This suggests that for the same degree of liver function between HCV and ethanol etiologies, the ethanol hepatopathy have more liver stiffness, most because of more fibrosis and therefore it showed higher values in elastography.

The value of MELD score is well established as prognostic evaluation in patients with cirrhosis and in list for liver transplantation. In Brazil, this score was implemented in 2006 for organ allocation, and was demonstrated retrospectively by us an increase in the number of liver transplants performed in School of Medicine, University of São Paulo from 2002 to 2012. We noted in this study that the value of MELD score was significant with higher patients with cirrhosis assessed by elastography who died (p=0.035) and higher values for liver elastography (FibroScan) with a significant trend (p=0.098) in these same patients, demonstrating a positive relationship with mortality.

There were several limitations of this study. For example, we had a selection bias due to all our patients were in cirrhosis or severe end of liver disease. Also, to get a good correlation of non-invasive elastography and clinical data,
to detect HCC is necessary to validate with a higher number of cases. However, we presented two independent risk factors for hepatocellular carcinoma like the HCV etiology and increased serum levels of AFP were demonstrated. We could also identify a positive correlation between cases with increased values of MELD score and the values of FibroScan in patients who died.

The potential clinical benefit of this study with liver elastography measurements, Doppler ultrasound and clinical findings in these patients is that patients with HCV and HCC should be prioritized when liver stiffness is >26 kPa and higher values could predict morbimortality. This could alter organ allocation priorities and improve clinical management with more prospective imaging on waiting lists. A longer, better-designed prospective study is needed before concrete recommendations for change can be proposed.

CONCLUSIONS

The elastography is an important non-invasive tool for monitoring severe cirrhosis and may help in management of hepatocellular carcinoma with the association of serum alpha fetoprotein, clinical, laboratory and imaging findings. However, liver elastography shows higher values in both HCC and cirrhosis livers. Finally, the evaluation of elastography showed that liver elastography and MELD scores can predict risk of mortality.

ACKNOWLEDGEMENTS

The authors thank the Laboratory of Epidemiology and Statistics of Department of Gastroenterology, School of Medicine – University of São Paulo, SP, Brazil who provided all the statistical analysis and Alves de Queiroz Family Found for Research.

REFERENCES

1. Baranova A, Lal P, Birendic A, Younissi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011 Aug 17;11:91.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1035.
3. Crespo G, Fernández-Varo G, Marín Z, Casals G, Miquel R, Martínez SM, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012 Aug;57(2):281-7.
4. Da Silva LC, Montenegro MR, de Godoy A, Pontes JF. An evaluation of the problem of hepatic cirrhosis as seen in São Paulo, Brazil. Ill. Postnecrotic cirrhosis: clinical aspects. Gastroenterology, 34:1121, 1958.
5. de Ledinghen V, Vergnol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices. 2010 Nov;7(6):811-23.
6. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:930-943.
7. Foucher J, Chanteloup E, Vergnol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55(3):403-8.
8. Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaumard M, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007 Apr;46(4):628-34.
9. Ling W, Lu Q, Lu C, Quan J, Ma L, et al. Effects of vascularity and differentiation of hepatocellular carcinoma on tumor and liver stiffness: in vivo and in vitro studies. Ultrasound Med Biol. 2014 Apr;40(4):739-46.
10. Muszaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C: Transient elastography. Hepatology. 2009;49(6):1954-61.
11. Mazzaferrro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Boffetti F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-700.
12. Montenegro MR, da Silva LC, Pontes JF. An evaluation of the problem of hepatic cirrhosis as seen in São Paulo, Brazil. I. Criteria for classification and incidence. Gastroenterology, 33: 178, 1957.
13. Nacif LS, Andrusa W, Martino RB, Santos VR, Pinheiro RS, Haddad LB, et al. Adoption of MELD score increases the number of liver transplant. Arq Bras Cir Dig. 2014 Sep;27(3):201-3.
14. Nacif LS, Pinheiro RS, Pécora RA, Ducatti L, Rocha-Santos V, Andrusa W, et al. Late acute rejection in liver transplant: a systematic review. Arq Bras Cir Dig. 2015 Jul-Sep;28(3):212-5.
15. Diagnosis-Fibrosis-By, On-Shell, Liver stiffness measurement. J Hepatol. 2012;57(2):281-7.
16. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010;78 Suppl 1:7-10.
17. Sá GP, Vicentine FP, Salcedas-Netto AA, Matos CA, Romero LR, Tejada DF, Massarollo PC, Lopes-Filho GJ, Gonzalez AM. Liver transplantation for carcinoma hepatocellular in São Paulo: 414 cases by the Milan/Brazil Criteria. Arq Bras Cir Dig. 2016 Nov-Dec;29(4):240-245.
18. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010;78 Suppl 1:7-10.
19. Sporea I, Sirli RL, Deleanu A, et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med 2011; 32(Suppl 1): S46–52.
20. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonicographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54(6):1987-97.
21. Zanchet MV, Silva LL, Matias JE, Coelho JC. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54(6):1987-97.
22. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005 Jan;41(1):48-54.